ADC Therapeutics SA — Form 6-K Summary
Business context and reporting period
ADC Therapeutics SA filed a Form 6-K as a foreign private issuer for the month of March 2022. The filing was signed and dated March 1, 2022, and identifies the company’s principal executive office in Epalinges, Switzerland. The filing indicates that the company files annual reports on Form 20-F.
Financial metrics
The submitted filing text is a cover page and does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, operating metrics, or other financial results.
Material changes versus the prior comparable period
The filing text does not provide financial or operating information sufficient to identify changes versus a prior comparable period.
Guidance, outlook, risks, contingencies, and unusual items
The filing references Exhibit 99.1, described as a press release dated March 1, 2022, but the press release content is not included in the provided filing text. Accordingly, no guidance, outlook, risk disclosure, contingency, or unusual item can be assessed.
Facts investors should verify
- Obtain and review Exhibit 99.1, the March 1, 2022 press release.
- Verify whether the omitted press release contains financial results, clinical or regulatory developments, guidance, or material risk disclosures.
- Consult the company’s applicable Form 20-F and subsequent filings for financial statements and liquidity information.